### Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 3

BIOSANTE PHARMACEUTICALS INC Form 3 July 01, 2013 FORM 3 UNITED STATES SECURIT Washin

# **M 3** UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

#### OMB APPROVAL

OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

(Instr. 4)

1. Name and A Person <u>*</u> MERIDI PARTNERS	AN VENT		2. Date of Event Requiring Statement (Month/Day/Year) 06/19/2013	<sup>ing</sup> 3. Issuer Name <b>and</b> Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [BPAX]				
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)	
259 N. RAI	DNOR-CH	ESTER						
ROAD, SU	ITE 130			(Check	all applicable	)		
	(Street)			Director Officer (give title below	Othe	r	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person	
RADNOR,	A PAA 19(	087					_X_Form filed by More than One Reporting Person	
(City)	(State)	(Zip)	Table I - N	Non-Derivat	tive Securit	ies Be	neficially Owned	
1.Title of Secu (Instr. 4)	ırity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	•	
Reminder: Rep owned directly			ach class of securities benefic	<sup>ially</sup> S	EC 1473 (7-02	2)		
	inforı requi	mation cont red to respo	pond to the collection of ained in this form are not ond unless the form displ MB control number.	t				
r	Fable II - De	rivative Secu	rities Beneficially Owned (e	.g., puts, calls,	warrants, op	tions, c	onvertible securities)	
1. Title of Der	ivative Secur	ity 2. Da	ate Exercisable and 3. Title	and Amount o	f 4.	5.	6. Nature of Indirect	

Derivative Security	2. Date Exerc	isable and	3. Title and	Amount of	4.	5.	6. Nature of Indirect	
	Expiration Date		Securities Underlying		Conversion	Ownership	Beneficial Ownership	
	(Month/Day/Year)		Derivative S	ecurity	or Exercise	Form of	(Instr. 5)	
			(Instr. 4)		Price of	Derivative		
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)		

Shares or Indirect (I) (Instr. 5)

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MERIDIAN VENTURE PARTNERS II LP 259 N. RADNOR-CHESTER ROAD, SUITE 130 RADNOR, PA 19087	Â	ÂX	Â	Â		
Meridian Venture Partners II GP, L.P. 259 N. RADNOR-CHESTER ROAD, SUITE 130 RADNOR, PA 19087	Â	ÂX	Â	Â		
Meridian Venture Partners II, Co. 259 N. RADNOR-CHESTER ROAD, SUITE 130 RADNOR, PA 19087	Â	ÂX	Â	Â		
Signatures						
/s/ Roland S. Chase, as 07/01/20 attorney-in-fact	013					
**Signature of Reporting Person Date						

# **Explanation of Responses:**

## No securities are beneficially owned

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.